Direct therapeutic targeting of IDH2 using small molecule inhibition alongside RUX has shown superior efficacy to monotherapy in JAK2 V617F and IDH2 mutant murine MPN models and synergistic effects in dual mutated primary MPN cells [71]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.